The previous finding by Chuang et al. (18) and the data in this report suggest that verteporfin (both high-dose and low-dose) efficiently suppresses GLK overexpression–induced IL-17A overproduction in inflammatory T cells from patients with SLE or RA. Here, GCK is linked to systemic lupus erythematosus.